AI assistant
Mersana Therapeutics, Inc. — Director's Dealing 2024
Oct 7, 2024
34702_dirs_2024-10-07_0bef0cd3-aa2c-43d7-a344-5ea2fe542401.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Mersana Therapeutics, Inc. (MRSN)
CIK: 0001442836
Period of Report: 2024-10-01
Reporting Person: Bala Mohan (SVP, Chief Development Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-10-01 | Common Stock | M | 50000 | — | Acquired | 64052 | Direct |
| 2024-10-02 | Common Stock | S | 8089 | $2.00 | Disposed | 55963 | Direct |
| 2024-10-03 | Common Stock | S | 5598 | $1.96 | Disposed | 50365 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-10-01 | Restricted Stock Unit | $ | M | 50000 | Disposed | Common Stock (50000) | Direct |
Footnotes
F1: Represents shares of common stock received upon vesting of the restricted stock units ("RSUs") awarded to the Reporting Person on September 5, 2023.
F2: Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.82 to $2.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.92 to $2.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: Each RSU represents the contingent right to receive one share of common stock of the Issuer.
F6: Fully vested as of October 1, 2024.